CEO Martin VanTrieste (Civica Rx)
Flush with cash to change the generics supply chain, Civica Rx looks to break ground on first in-house manufacturing site
Looking to overhaul the generics supply chain for future pandemics, the Trump administration in May doled out a hefty four-year, $354 million contract to the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.